版權(quán)說明:本文檔由用戶提供并上傳,收益歸屬內(nèi)容提供方,若內(nèi)容存在侵權(quán),請進(jìn)行舉報(bào)或認(rèn)領(lǐng)
文檔簡介
China-JapanCardiovascularForum2019NewStrategiesforImmune-mediatedHeartDiseasesMitsuakiIsobeDepartmentofCardiovascularMedicineTokyoMedicalandDentalUniversityImmune-mediatedheartdiseasesIschemia-reperfusioninjuryAtherosclerosisRestenosisCardiacallograftrejectionCardiacallograftvasculopathyMyocarditisCongestiveheartfailureArrhythmiaImmune-mediatedheartdiseasesIschemia-reperfusioninjuryAtherosclerosisRestenosisCardiacallograftrejectionCardiacallograftvasculopathyMyocarditisCongestiveheartfailureArrhythmiaInflammationincoronaryarteriosclerosisandatherogenesisPPARγ(Peroxisomeproliferator-activatedreceptor-γ)NFκBAcutecardiacallograftrejectionEctopichearttransplantionrecipients:C3H/Hedonors:BALB/cfullmismatchAdministrationofpioglitazone(3mg/kg/day)totherecipientmice.MurinehearttransplantationProlongationofheartgraftbypioglitazone1Survival
Rate0.80.60.4*Pioglitazone(3mg/kg/day)Controlchow0.2010203040506070*p<0.05PostoperativeDaysKosuge,Suzuki,Isobe:Circulation113:2613-2622、2019SuppressionofTcellProliferationbyPioglitazoneinMixedLymphocyteReaction*0.8**Optical
Density0.60.4*p<0.050.20R:responder(recipient)S:stimulator(donor)Pio:pioglitazoneChroniccardiacrejectionGraftarterialdisease(GAD)AcceleratedcoronarysclerosisGraftvasculopathyCardiacallograftvasculopathyMyocardiumRCASmallarteriesPathology:DiffuseintimalthickeningofsmalltolargecoronaryarteriesProgression:monthstoyearsRiskfactors:CMVinfectionepisodesofacuterejectionTherapy:?LAD8-y-oboyLCXChroniccardiacallograftrejectionCardiacallograftvasculopathyrecipients:C57BL/6donors:Bm12classIImismatch-10714212835424956daysControlchowPioglitazone(3mg/kg/day)Telmisartan(10mg/kg/day)sacrificeAttenuationofGraftArteriosclerosisbyTreatmentwithPioglitazoneorTelmisartanp<0.05ControlLuminal
occlusion
(%)TelmisartanControlPioglitazonep<0.05Pioglitazone8WeeksafterTransplantationControlTelmisartanKosuge,Suzuki,Isobe:Circulation2019SMCProliferationAssaySMCsAortaPioglitazonetelmisartanactivatedsplenocytesProliferationSuppressionofSMCproliferation?SuppressionofSMCProliferationafterInteractionwithSplenocytesbyPioglitazoneorTelmisartan*5.0**0.70.60.50.40.30.2***OpticalDensity4.03.02.01.000.10Summary1?PPARγisassociatedwithpathophysiologyofimmune-mediatedheartdiseases.?PPAR-γagonists(pioglitazoneandtelmisartan)areeffectiveinsuppressingexperimentalcardiacallograftrejection(acuterejectionandallograftvasculopathy).ReferencesKosuge,Suzuki,Isobe:Circulation113:2613-2622,2019Isobe,Kosuge,Suzuki:ATVB,26:1447-1456,2019Kosuge,Suzuki,Isobe:ATVB,26:2660-2665,2019Onai,Suzuki,Maejima:AmJPhysiol,292,H530-538,2019Kosuge,Suzuki,Isobe,Transplanation,inpressMaejima,Suzuki,Okada,Isobe:insubmissionInflammationincoronaryarteriosclerosisandatherogenesisPPARγ(Peroxisomeproliferator-activatedreceptor-γ)NFκBLPSTNFTCellTCRNFκBRoleofNF-kBinCardiovascularDiseasesStimuliAnoxiaReactiveoxygenspeciesLPSCytokines(IL-1β,TNFα)Re-oxygenationLipoproteinThrombinNF-κBActivationGeneExpressionCytokines(IL-1β,TNFα)iNOS,COX-2Adhesionmolecules(ICAM-1,VCAM-1)Immunoreceptors(MHCclassI,II)IL-6,M-CSF,GM-CSFChemokines(MCP-1,…)Acutephaseprotein(CRP,…)HeartfailureVascularremodelingAllograftrejectionMyocarditisReperfusioninjuryVentricularremodelingNF-κBdecoy-MechanismofAction-StimuliI-?BkinasesI-?BkinasesInflammatorymoleculesDegradationCellMembraneI-κBp50p65PI-κBp50p65I-κBXmRNANF-?Bp50p65p50p65DecoyDecoyNucleusp50p65XInflammatorygenesCis-ElementAcuteMyocarditisExperimentalAllergicMyocarditisinRatsImmunizationLewisratswereimmunizedwithporcinecardiacmyosin.InvivogenetransferInjectionofHVJ-liposome-NFκBdecoyatcoronarycuspFITC-labeledDecoyinRatHeartDay0,7or1421daysaftertransfectionNFkBdecoyreducesextentofautoimmunemyocariditisControl(%)1008060NFkBdecoy40200UTSDday0day7day14Myocarditis-affectedarea(injectionatday7)(YokosekiO,IsobeM,CircRes2019)MethodofgenetransfertocardiacallograftDonorHVJ-liposomeHVJ-DonorHeartDecoyTransfectionTransfection:10min,4CIschemictime:30minRecipient28daysHistologicalanalysisEffectofNFκBdecoyonGADEvGstainingPDGF-BmRNAVCAM-1ScrambledecoyNFκBdecoy(Suzuki,Isobe,GeneTherapy,2019)GeneTransferSystemDecoy+microbubblecomplexUltrasound(US)WireinjuryInhibitionofintimalhyperplasiabyNF-kBdecoytransfectionNeointimalformation(I/M)I/M2p<0.05NoUltrasound1*(-)(+)(+)(+)(-)(-)(+)(+)(-)(+)(-)(+)DecoyMicrobubbleUltrasoundUltrasoundEvG,Day14ClinicaltrialforpreventionofcoronaryrestenosisafterangioplastyJapanTrialtoPreventRestenosisAfterStentusingNFkBdecoyOligodeoxynucleotidesasGeneTherapy(J-PRAN)ThefirstclinicaltrialofgenetherapyforheartdiseaseinJapanCollaborationwithKyushuUniv,OsakaUniv,andTokyoMedandDentUniv.DecoytransfectionafterstentimplantationNovirusvectorDosetrialforsafetyEvaluationat6monthsbyangiographyandIVUSChannelBalloon(Remedy)NF-kBdecoy:case1(49-y-omale)Before2.5yearsafter#2:decoy#2:decoyDecember6,2019(Suzuki,Isobe,CircJ2019)May22,2019ResultsPatientID(dose)12I-001I-002(1mg)(1mg)genderMMage4475%QCABeforePCI%QCAAfterPCI%QCA6molater759000025345678910Q-001Q-002Q-004Q-005Q-007Q-009Q-012Q-013(1mg)(1mg)(1mg)(1mg)(2mg)(2mg)(2mg)(2mg)MMMFFMMM757847795857706690909099000045502555909090999990909000250000025476725502590251112131415161718I-003Q-017Q-018Q-019Q-022Q-028Q-032A-001(2mg)(2mg)(4mg)(4mg)(4mg)(4mg)(4mg)(4mg)MMMMMMMM565476665785-9975909900002525―*68.953(JGeneMed,inpress)SummaryofQCAPatientswithRestenosis(>75%byQCA)NegativePositivePatients171BeforePCIAfterPCIRates94.1%5.9%6Mo.LaterAverage%Restenosis(byQCA)%Restenosis88.51.539.6ConclusionsPPARγandNFκBaregoodmoleculartargetsfortreatmentofimmune-mediatedcardiovasculardiseases.Furtherstudiesshouldbeconductedtoexplorethepossibilitytodevelopnewtherapeuticstrategies.AcknowledgementTokyoMedicalandDentalUniversityJun-ichiSuzukiHisanoriKosugeNoritakaKogaNorikoTamuraMasahitoOgawaRyuichiMorishitaYasufumiKanedaKensukeEgashiraHiroshiItoOsakaUniversityKyushuUniversityAkitaUniversitySuppressionofCytokinesExpressioninAllograftsbyTreatmentwithPioglita
溫馨提示
- 1. 本站所有資源如無特殊說明,都需要本地電腦安裝OFFICE2007和PDF閱讀器。圖紙軟件為CAD,CAXA,PROE,UG,SolidWorks等.壓縮文件請下載最新的WinRAR軟件解壓。
- 2. 本站的文檔不包含任何第三方提供的附件圖紙等,如果需要附件,請聯(lián)系上傳者。文件的所有權(quán)益歸上傳用戶所有。
- 3. 本站RAR壓縮包中若帶圖紙,網(wǎng)頁內(nèi)容里面會有圖紙預(yù)覽,若沒有圖紙預(yù)覽就沒有圖紙。
- 4. 未經(jīng)權(quán)益所有人同意不得將文件中的內(nèi)容挪作商業(yè)或盈利用途。
- 5. 人人文庫網(wǎng)僅提供信息存儲空間,僅對用戶上傳內(nèi)容的表現(xiàn)方式做保護(hù)處理,對用戶上傳分享的文檔內(nèi)容本身不做任何修改或編輯,并不能對任何下載內(nèi)容負(fù)責(zé)。
- 6. 下載文件中如有侵權(quán)或不適當(dāng)內(nèi)容,請與我們聯(lián)系,我們立即糾正。
- 7. 本站不保證下載資源的準(zhǔn)確性、安全性和完整性, 同時也不承擔(dān)用戶因使用這些下載資源對自己和他人造成任何形式的傷害或損失。
最新文檔
- 藝術(shù)研究開題報(bào)告模板
- 執(zhí)行庭個人總結(jié)
- 常州冷庫課程設(shè)計(jì)
- 帶電檢測課程設(shè)計(jì)
- 師范生漢字運(yùn)用課程設(shè)計(jì)
- 布依美食的研究報(bào)告
- 市政公路施工方案
- 工資信息系統(tǒng)課程設(shè)計(jì)
- 工藝品課程設(shè)計(jì)
- 工程項(xiàng)目管理課程設(shè)計(jì)
- 農(nóng)村積分超市實(shí)施方案(2篇)
- PICC維護(hù)流程及常見并發(fā)癥的處理成品
- 壓軸題03 電路故障綜合(解析版)-2024年中考物理壓軸題專項(xiàng)訓(xùn)練
- 7往事依依省公開課一等獎新名師課比賽一等獎?wù)n件
- 人教版高中英語必修一年級上冊冊單元訓(xùn)練題 全冊
- 專業(yè)課程說課省公開課金獎全國賽課一等獎微課獲獎?wù)n件
- 《SketchUp三維輔助設(shè)計(jì)》課件-02 SketchUp的繪圖環(huán)境
- 2024屆高考英語復(fù)習(xí):2022年全國新高考Ⅰ卷讀后續(xù)寫真題-David的賽跑課件
- 《傳播學(xué)教程》教學(xué)大綱
- 2024年新《公司法》修訂重點(diǎn)解讀
- 中央空調(diào)改造施工進(jìn)度計(jì)劃及保證工期措施
評論
0/150
提交評論